GT200000183AA - Aminoacidos biciclicos como agentes farmaceuticos - Google Patents

Aminoacidos biciclicos como agentes farmaceuticos

Info

Publication number
GT200000183AA
GT200000183AA GT200000183AK GT200000183K GT200000183AA GT 200000183A A GT200000183A A GT 200000183AA GT 200000183A K GT200000183A K GT 200000183AK GT 200000183 K GT200000183 K GT 200000183K GT 200000183A A GT200000183A A GT 200000183AA
Authority
GT
Guatemala
Prior art keywords
amino acids
bicycle
pharmaceutical agents
disorders
compounds
Prior art date
Application number
GT200000183AK
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000183AA publication Critical patent/GT200000183AA/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Abstract

LOS COMPUESTOS DE LA PRESENTE INVENCION SON AMINOACIDOS BICICLICOS UTILES EN EL TRATAMIENTO DE LA EPILEPSIA, LOS ATAQUES DE DESMAYO, HIPOQUINESIA, TRASTORNOS CRANEANOS, TRASTORNOS NEURODEGENERATIVOS, DEPRESION, ANSIEDAD, PANICO, DOLOR, ARTRITIS, TRASTORNOS NEUROPATOLOGICOS, Y TRASTORNOS DEL SUEÑO. LOS PROCESOS PARA LA PREPARACION DE LOS PRODUCTOS FINALES Y LOS INTERMEDIARIOS DE SINTESIS UTILES EN EL PROCESO ESTAN INCLUIDOS. TAMBIEN ESTAN INCLUIDAS LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UNO O MAS DE LOS COMPUESTOS.
GT200000183AK 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos GT200000183AA (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
GT200000183AA true GT200000183AA (es) 2005-06-17

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200000183AK GT200000183AA (es) 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos
GT200000183A GT200000183A (es) 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200000183A GT200000183A (es) 1999-10-20 2000-10-19 Aminoacidos biciclicos como agentes farmaceuticos.

Country Status (50)

Country Link
US (2) US6689906B1 (es)
EP (2) EP1506955B1 (es)
JP (2) JP3632191B2 (es)
KR (2) KR100566462B1 (es)
CN (1) CN1165518C (es)
AP (2) AP2002002517A0 (es)
AR (2) AR026087A1 (es)
AT (2) ATE358116T1 (es)
AU (2) AU778871B2 (es)
BG (2) BG108860A (es)
BR (1) BR0014972B1 (es)
CA (1) CA2386297C (es)
CO (1) CO5280060A1 (es)
CR (1) CR6620A (es)
CU (1) CU23112A3 (es)
CZ (1) CZ295960B6 (es)
DE (2) DE60019628T2 (es)
DO (1) DOP2000000083A (es)
DZ (1) DZ3197A1 (es)
EA (1) EA005206B1 (es)
EC (1) ECSP045393A (es)
EE (1) EE200200211A (es)
ES (2) ES2282785T3 (es)
GE (1) GEP20043297B (es)
GT (2) GT200000183AA (es)
HK (1) HK1049826B (es)
HN (1) HN2000000224A (es)
HR (2) HRP20020428B1 (es)
HU (1) HUP0203325A3 (es)
IL (3) IL149143A0 (es)
IS (2) IS6348A (es)
MA (1) MA26842A1 (es)
MX (1) MXPA02003229A (es)
MY (1) MY127678A (es)
NO (2) NO20021780L (es)
NZ (1) NZ517961A (es)
OA (1) OA12070A (es)
PA (1) PA8505201A1 (es)
PE (1) PE20010740A1 (es)
PL (1) PL354607A1 (es)
PT (1) PT1226110E (es)
SI (1) SI1226110T1 (es)
SK (1) SK5232002A3 (es)
SV (1) SV2001000188A (es)
TR (2) TR200201094T2 (es)
TW (2) TW200505824A (es)
UA (1) UA72931C2 (es)
WO (1) WO2001028978A1 (es)
YU (2) YU73004A (es)
ZA (1) ZA200202543B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
WO2002000209A2 (en) * 2000-06-26 2002-01-03 Warner-Lambert Company Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
OA12504A (en) 2001-04-19 2006-05-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids.
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04004105A (es) * 2002-01-31 2004-11-29 Warner Lambert Co Metodo de tratamiento de tinnitus.
JP2005523281A (ja) * 2002-02-22 2005-08-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
EP1545491A1 (en) * 2002-08-15 2005-06-29 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
ES2433890T3 (es) 2007-09-28 2013-12-12 Daiichi Sankyo Company, Limited Derivado de aminoácido bicíclico
KR101674700B1 (ko) 2009-03-26 2016-11-09 다이이찌 산쿄 가부시키가이샤 2고리성 γ-아미노산 유도체의 제조 방법
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
EP2719676B1 (en) 2011-06-08 2017-12-13 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
CN104245951B (zh) 2012-04-10 2018-08-24 第一三共株式会社 使用酶对二环化合物光学拆分的方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PL199794B1 (pl) 1997-10-27 2008-10-31 Warner Lambert Co Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów

Also Published As

Publication number Publication date
IL149143A0 (en) 2002-11-10
AR045456A2 (es) 2005-10-26
DZ3197A1 (fr) 2001-04-26
HRP20020428B1 (en) 2006-02-28
SV2001000188A (es) 2001-09-07
HUP0203325A3 (en) 2003-12-29
CN1165518C (zh) 2004-09-08
DE60034157D1 (de) 2007-05-10
NO20043663L (no) 2002-04-16
ZA200202543B (en) 2003-09-23
MXPA02003229A (es) 2002-09-30
CA2386297A1 (en) 2001-04-26
EP1506955A1 (en) 2005-02-16
OA12070A (en) 2003-11-10
EP1226110B1 (en) 2005-04-20
EP1226110A1 (en) 2002-07-31
ECSP045393A (es) 2004-10-23
AP2004003186A0 (en) 2004-12-31
TW200505824A (en) 2005-02-16
AU1092001A (en) 2001-04-30
HRP20020428A2 (en) 2005-02-28
EE200200211A (et) 2003-06-16
UA72931C2 (uk) 2005-05-16
IS7497A (is) 2004-10-08
US20040152779A1 (en) 2004-08-05
JP3744928B2 (ja) 2006-02-15
DOP2000000083A (es) 2002-03-30
BR0014972B1 (pt) 2011-09-06
MY127678A (en) 2006-12-29
ATE358116T1 (de) 2007-04-15
JP3632191B2 (ja) 2005-03-23
PA8505201A1 (es) 2002-08-29
YU29302A (sh) 2005-06-10
KR100593349B1 (ko) 2006-06-26
IS6348A (is) 2002-04-17
EA200200293A1 (ru) 2002-10-31
AP2002002517A0 (en) 2002-06-30
SI1226110T1 (en) 2005-08-31
US6835751B2 (en) 2004-12-28
HUP0203325A2 (hu) 2003-02-28
AU2005201268A1 (en) 2005-04-21
TR200201094T2 (tr) 2002-09-23
AR026087A1 (es) 2002-12-26
HN2000000224A (es) 2001-04-11
CA2386297C (en) 2010-02-09
HK1049826A1 (en) 2003-05-30
DE60019628D1 (de) 2005-05-25
JP2003512348A (ja) 2003-04-02
DE60019628T2 (de) 2006-01-19
NO20021780D0 (no) 2002-04-16
PE20010740A1 (es) 2001-07-27
PL354607A1 (en) 2004-01-26
NO20021780L (no) 2002-04-16
KR100566462B1 (ko) 2006-03-31
US6689906B1 (en) 2004-02-10
BG106719A (bg) 2003-02-28
IL164060A0 (en) 2005-12-18
DE60034157T2 (de) 2007-12-13
CO5280060A1 (es) 2003-05-30
EP1506955B1 (en) 2007-03-28
CZ20021310A3 (cs) 2003-05-14
HRP20040709A2 (en) 2004-12-31
YU73004A (sh) 2005-11-28
CN1382118A (zh) 2002-11-27
TWI225855B (en) 2005-01-01
PT1226110E (pt) 2005-07-29
CR6620A (es) 2004-02-02
BG108860A (en) 2006-03-31
AU778871B2 (en) 2004-12-23
KR20020040900A (ko) 2002-05-30
BR0014972A (pt) 2002-07-16
JP2005036009A (ja) 2005-02-10
MA26842A1 (fr) 2004-12-20
EA005206B1 (ru) 2004-12-30
HK1049826B (zh) 2005-02-25
ATE293590T1 (de) 2005-05-15
TR200500221T2 (tr) 2005-03-21
IL149143A (en) 2007-02-11
NZ517961A (en) 2002-12-20
ES2282785T3 (es) 2007-10-16
CZ295960B6 (cs) 2005-12-14
WO2001028978A1 (en) 2001-04-26
SK5232002A3 (en) 2003-07-01
CU23112A3 (es) 2006-02-27
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
ES2237464T3 (es) 2005-08-01
KR20060013701A (ko) 2006-02-13

Similar Documents

Publication Publication Date Title
GT200000183AA (es) Aminoacidos biciclicos como agentes farmaceuticos
PA8543501A1 (es) Aminoácidos bicíclicos o tricíclicos condensados
ES2176668T3 (es) Aminoacidos ciclicos novedosos como agentes farmaceuticos.
BR9813656A (pt) Aminas como agentes farmacêuticos
BR9712651A (pt) ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
CR7802A (es) Derivados de prolina que presentan afinidad por la subunidad alfa-2-delta del canal de calcio
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
MX9806069A (es) Novedosos amino acidos ciclicos substituidos como agentes farmaceuticos.
UY24354A1 (es) Composiciones farmacéuticas que contienen epinastina
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
PA8629801A1 (es) Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
PA8529701A1 (es) Compuestos retinoides
ECSP034804A (es) Aminoácidos bicíclicos o tricíclicos condensados
BR0011236A (pt) Amino heterociclos úteis como agentes farmacêuticos
ECSP003707A (es) Diazepanes
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
GT200100197A (es) Derivados de triptamina y compuestos analogos, y formulaciones farmaceuticas que lo contienen.
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
UY27262A1 (es) Aminoácidos bicíclicos o tricíclicos condensados